Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Phosphate adsorbing agent for blood processing, blood processing system and blood processing method

a phosphate adsorbing agent and blood processing technology, applied in the direction of other chemical processes, blood circulation devices, separation processes, etc., can solve the problems of impaired renal function, increased risk of heart failure, and inability to properly excrete excessive phosphate from their bodies,

Inactive Publication Date: 2018-11-15
ASAHI KASEI MEDICAL CO LTD
View PDF0 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention is a porous article that can control the concentration of phosphate in the blood. This can help to regulate the body's phosphate levels and keep them within an appropriate range.

Problems solved by technology

On the other hand, for example, kidney disease patients, such as chronic renal failure patients, who have impaired renal functions cannot properly excrete excessive phosphate from their bodies.
Such renal bone disease complicated with hypercalcemia increases the risk of developing heart failure due to cardiovascular calcification.
Among others, maintenance dialysis patients who are chronic renal failure patients lack renal functions serving as the main elimination route of phosphate and therefore substantially lack the function of excreting phosphate into urine.
In fact, sufficient excretion cannot be achieved by current dialysis time and dialysis conditions.
As mentioned above, the dialysis therapy alone is not sufficiently effective for removing phosphate.
Therefore, it is difficult to control phosphate concentrations in the body by the diet therapy.
In the drug therapy, however, the amount of the phosphate adsorbing agent drunk at the time of each meal is considerably large.
Therefore, vomiting, a feeling of fullness, constipation, accumulation of the drug in the body, etc. occur with high probability as adverse reactions of the administered phosphate adsorbing agent.
Therefore, drug compliance is very low (reportedly 50% or less) due to these adverse reactions.
Thus, it is difficult both for doctors and for patients to control phosphate concentrations by use of the drug.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Phosphate adsorbing agent for blood processing, blood processing system and blood processing method
  • Phosphate adsorbing agent for blood processing, blood processing system and blood processing method
  • Phosphate adsorbing agent for blood processing, blood processing system and blood processing method

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0237]220 g of N-methyl-2-pyrrolidone (NMP, Mitsubishi Chemical Corp.) and 200 g of a hydrous cerium oxide powder having an average particle size of 30 μm (Iwatani Corp.) were added to a stainless ball mill pot (capacity: 1 L) packed with 1.5 kg of stainless balls having a diameter of 5 mmϕ, and subjected to crushing and mixing treatment at 75 rpm for 150 minutes to obtain yellow slurry. To the obtained slurry, 4 g of polyvinylpyrrolidone (PVP, BASF Japan Ltd., Luvitec K30 Powder (trade name)) and 10 g of a copolymer consisting of 91.5% by mass of acrylonitrile, 8.0% by mass of methyl acrylate and 0.5% by mass of sodium methallylsulfonate and having limiting viscosity [η]=1.2 (organic polymer resin, PAN) were added, and the mixture was warmed to 60° C. in a dissolution vessel and dissolved with agitation using an agitation blade to obtain a homogeneous slurry solution for shape forming.

[0238]The obtained slurry solution for shape forming was warmed to 60° C. and supplied to the insi...

example 2

[0265]A spherical porous formed article was obtained in the same way as the method described in Example 1 except that: the temperature of the coagulating liquid was set to 60° C.; and the temperature and relative humidity of the spatial portion were controlled to 37° C. and 100%, respectively.

example 3

[0266]A spherical porous formed article was obtained in the same way as the method described in Example 1 except that the amount of the hydrous cerium oxide powder added was increased from 200 g to 300 g.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
pore sizeaaaaaaaaaa
particle sizeaaaaaaaaaa
treatment timeaaaaaaaaaa
Login to View More

Abstract

The present invention relates to a phosphate adsorbing agent for blood processing comprising a porous formed article comprising an organic polymer resin and an inorganic ion adsorbent and having the most frequent pore size of 0.08 to 0.70 μm measured with a mercury porosimeter. The present invention also relates to a blood processing system and a blood processing method involving the phosphate adsorbing agent for blood processing.

Description

TECHNICAL FIELD[0001]The present invention relates to a phosphate adsorbing agent for blood processing and a blood processing system. The present invention further relates to a blood processing method using the phosphate adsorbing agent for blood processing.BACKGROUND ART[0002]In healthy adults whose kidney functions normally, excessive phosphate in the body is excreted mainly as urine from the body. On the other hand, for example, kidney disease patients, such as chronic renal failure patients, who have impaired renal functions cannot properly excrete excessive phosphate from their bodies. Therefore, phosphate accumulates gradually in the body, causing a disease such as hyperphosphatemia.[0003]Sustained hyperphosphatemia causes secondary hyperparathyroidism which results in renal bone disease characterized by symptoms such as painful bone, fragile bone, bone deformation, and susceptibility to fracture. Such renal bone disease complicated with hypercalcemia increases the risk of dev...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61M1/16A61M1/36B01J20/06B01J20/02B01J20/28B01D71/68B01D71/58B01D15/00
CPCA61M1/1621A61M1/3687B01J20/06B01J20/0211B01J20/28085B01J20/28059B01J20/28061B01J20/28004B01D71/68B01D71/58B01D15/00A61M1/16A61M1/36B01J20/08B01J20/10B01J20/28B01J20/26B01J2220/46
Inventor MORITA, NAOKITAJIMA, HIROSHISASAKI, RYOUNAGAI, HIROKAZUOMORI, AKIHIRO
Owner ASAHI KASEI MEDICAL CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com